Evidence map›Paper›PMID 26015500›Full record

ArticlemBio2015

Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection.

Allison L Totura, Alan Whitmore, Sudhakar Agnihothram, Alexandra Schäfer, Michael G Katze, Mark T Heise, Ralph S Baric

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in mBio, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04534803 (Bacillus Calmette-Guerin Against Covid-19 for Prevention and Amelioration of Severity Trial), which is not on this map. Cited by 313 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
313citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04534803 phase3withdrawnnot on this mapstarted 2021, after this paper: background citation

Bacillus Calmette-Guerin Against Covid-19 for Prevention and Amelioration of Severity Trial

TypeinterventionalSponsorHarvard Medical School (HMS and HSDM)Ran2021 to 2022Enrolled0ConditionsCovid19ArmsBCG Vaccine, Placebo
3 · Its place in the literature

Who cites it

313 citing papers in PubMed, 2 syntheses or guidelines pooled it, 463 citations in OpenAlex.

  1. Pooled it
  2. Meta-analysis of Effect of Statins in Patients with COVID-19.The American journal of cardiology · 2020
    Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Baohuoside I CombatedAntioxidants (Basel, Switzerland) · 2026
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

253 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Allison L ToturaDepartment of Microbiology and Immunology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA.
Alan WhitmoreDepartment of Genetics, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA.
Sudhakar AgnihothramDepartment of Epidemiology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA.
Alexandra SchäferDepartment of Epidemiology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA.
Michael G KatzeDepartment of Microbiology, University of Washington, Seattle, Washington, USA.
Mark T Heise
Ralph S Baricrbaric@email.unc.edu.
University of North Carolina at Chapel Hill · USUniversity of Washington · US

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
Unlocking Zika Virus Immune Control and Pathogenesis with the Collaborative CrossU19AI100625 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HEISE, MARK T · 2012 to 2021
$36.6M
Systems Biology Identifies Restriction Factors for West Nile VirusU19AI106772 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI LIVNY, MIRON · 2013 to 2017
$26.1M
NIAID NIH HHS HHSN272200800060CNIAID NIH HHS U19 AI100625NIAID NIH HHS U19 AI106772NIH HHS P51 OD010425
6 · The paper itself

Abstract

unlabelledToll-like receptors (TLRs) are sensors that recognize molecular patterns from viruses, bacteria, and fungi to initiate innate immune responses to invading pathogens. The emergence of highly pathogenic coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) is a concern for global public health, as there is a lack of efficacious vaccine platforms and antiviral therapeutic strategies. Previously, it was shown that MyD88, an adaptor protein necessary for signaling by multiple TLRs, is a required component of the innate immune response to mouse-adapted SARS-CoV infection in vivo. Here, we demonstrate that TLR3(-/-), TLR4(-/-), and TRAM(-/-) mice are more susceptible to SARS-CoV than wild-type mice but experience only transient weight loss with no mortality in response to infection. In contrast, mice deficient in the TLR3/TLR4 adaptor TRIF are highly susceptible to SARS-CoV infection, showing increased weight loss, mortality, reduced lung function, increased lung pathology, and higher viral titers. Distinct alterations in inflammation were present in TRIF(-/-) mice infected with SARS-CoV, including excess infiltration of neutrophils and inflammatory cell types that correlate with increased pathology of other known causes of acute respiratory distress syndrome (ARDS), including influenza virus infections. Aberrant proinflammatory cytokine, chemokine, and interferon-stimulated gene (ISG) signaling programs were also noted following infection of TRIF(-/-) mice that were similar to those seen in human patients with poor disease outcome following SARS-CoV or MERS-CoV infection. These findings highlight the importance of TLR adaptor signaling in generating a balanced protective innate immune response to highly pathogenic coronavirus infections. IMPORTANCE: Toll-like receptors are a family of sensor proteins that enable the immune system to differentiate between "self" and "non-self." Agonists and antagonists of TLRs have been proposed to have utility as vaccine adjuvants or antiviral compounds. In the last 15 years, the emergence of highly pathogenic coronaviruses SARS-CoV and MERS-CoV has caused significant disease accompanied by high mortality rates in human populations, but no approved therapeutic treatments or vaccines currently exist. Here, we demonstrate that TLR signaling through the TRIF adaptor protein protects mice from lethal SARS-CoV disease. Our findings indicate that a balanced immune response operating through both TRIF-driven and MyD88-driven pathways likely provides the most effective host cell intrinsic antiviral defense responses to severe SARS-CoV disease, while removal of either branch of TLR signaling causes lethal SARS-CoV disease in our mouse model. These data should inform the design and use of TLR agonists and antagonists in coronavirus-specific vaccine and antiviral strategies.

Indexed as

Immunity, InnateAdaptor Proteins, Vesicular TransportAnimalsBody WeightDisease SusceptibilityLungMice, KnockoutReceptors, InterleukinRespiratory Function TestsSevere acute respiratory syndrome-related coronavirusSignal TransductionSurvival AnalysisToll-Like Receptor 3Toll-Like Receptor 4Viral LoadAdaptor Proteins, Vesicular TransportReceptors, InterleukinTicam1 protein, mouseTicam2 protein, mouseTLR3 protein, mouseTlr4 protein, mouseToll-Like Receptor 3Toll-Like Receptor 4

Identifiers

PMID26015500
PMCPMC4447251
OpenAlexW2164013535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.